Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: Implications for anti-EGFR treatment response

被引：32

作者：

Boeckx C. ^{[1
]}

Weyn C. ^{[1
]}

Vanden Bempt I. ^{[2
]}

Deschoolmeester V. ^{[1
]}

Wouters A. ^{[1
]}

Specenier P. ^{[3
]}

Van Laer C. ^{[4
]}

Van Den Weyngaert D. ^{[5
]}

Kockx M. ^{[2
]}

Vermorken J.B. ^{[3
]}

Peeters M. ^{[1
,3
]}

Pauwels P. ^{[1
,6
]}

Lardon F. ^{[1
]}

Baay M. ^{[1
]}

机构：

[1] Center for Oncological Research (CORE) Antwerp, Laboratory of Cancer Research and Clinical Oncology, University of Antwerp, Wilrijk

[2] HistoGeneX, Berchem

[3] Department of Medical Oncology, Antwerp University Hospital, Edegem

[4] Department of Otolaryngology, Antwerp University Hospital, Edegem

[5] Department of Radiation Therapy, Antwerp University Hospital, Edegem

[6] Department of Pathology, Antwerp University Hospital, Edegem

来源：

BMC Research Notes | / 7卷 / 1期

关键词：

Cetuximab; EGFR inhibitors; EGFR tyrosine kinase mutations; EGFRvIII mutations; Head neck squamous cell carcinoma; HPV; KRAS mutations; Resistance;

D O I：

10.1186/1756-0500-7-337

中图分类号：

学科分类号：

摘要：

Background: Targeted therapy against the Epidermal Growth Factor Receptor (EGFR) is among the most promising molecular therapeutics for Head and Neck Squamous Cell Carcinoma (HNSCC). However, drug resistance limits the clinical efficacy of anti-EGFR monoclonal antibodies and no predictive biomarker has entered the clinic yet. Methods. A retrospective clinical study was performed utilizing pathological specimens from 52 newly diagnosed HNSCC patients. These patients were screened for mutations in EGFR and KRAS. Tyrosine kinase mutations in EGFR and KRAS mutations were evaluated by high resolution melting analysis (HRMA), whereas EGFRvIII was determined using one-step real-time PCR. Finally, patient samples were screened for HPV-DNA by GP5+/6+ PCR. Survival analysis was performed using Kaplan-Meier analysis and significance was calculated using log-rank statistic. Results: In our study population no EGFRvIII mutations were present. However, two silent mutations were found; T785T in exon 20 and R836R in exon 21 of the EGFR gene. Additionally, HRMA revealed an abnormal KRAS melting pattern in 7.0% of the samples. However, the KRAS StripAssay could confirm only one sample with a G12S mutation and none of these samples could be confirmed by direct sequencing. HPV DNA was present in 3/25 larynx and 9/27 oropharynx tumors. Conclusion: The low rate of EGFR and KRAS mutations in this Belgian HNSCC population suggests that these genes will probably not play a major role in predicting response to anti-EGFR therapy in HNSCC. Hence, other predictive markers need to be discovered in order to optimize EGFR targeting therapy. © 2014 Boeckx et al.; licensee BioMed Central Ltd.

引用

共 38 条

[1]

Graziano A., D'Aquino R., Tirino V., Desiderio V., Rossi A., Pirozzi G., The stem cell hypothesis in head and neck cancer, J Cell Biochem, 103, 2, pp. 408-412, (2008)

[2]

Vermorken J.B., Specenier P., Optimal treatment for recurrent/metastatic head and neck cancer, Ann Oncol, 21, SUPPL. 7, (2010)

[3]

Temam S., Kawaguchi H., El-Naggar A.K., Jelinek J., Tang H., Liu D.D., Lang W., Issa J.P., Lee J.J., Mao L., Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer, J Clin Oncol, 25, 16, pp. 2164-2170, (2007)

[4]

Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., Fu K.K., Milas L., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma, Cancer Res, 62, 24, pp. 7350-7356, (2002)

[5]

Murray S., Bobos M., Angouridakis N., Nikolaou A., Linardou H., Razis E., Fountzilas G., Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study, J Oncol, 2010, (2010)

[6]

Dittmann K., Mayer C., Rodemann H.P., Nuclear EGFR as novel therapeutic target: Insights into nuclear translocation and function, Strahlenther Onkol, 186, 1, pp. 1-6, (2010)

[7]

Molinolo A.A., Amornphimoltham P., Squarize C.H., Castilho R.M., Patel V., Gutkind J.S., Dysregulated molecular networks in head and neck carcinogenesis, Oral Oncol, 45, 4-5, pp. 324-334, (2009)

[8]

Boehm A.L., Sen M., Seethala R., Gooding W.E., Freilino M., Wong S.M., Wang S., Johnson D.E., Grandis J.R., Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck, Mol Pharmacol, 73, 6, pp. 1632-1642, (2008)

[9]

Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., Peyrade F., Benasso M., Vynnychenko I., De Raucourt D., Bokemeyer C., Schueler A., Amellal N., Hitt R., Platinum-based chemotherapy plus cetuximab in head and neck cancer, N Engl J Med, 359, 11, pp. 1116-1127, (2008)

[10]

Boeckx C., Baay M., Wouters A., Specenier P., Vermorken J.B., Peeters M., Lardon F., Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: Focus on potential molecular mechanisms of drug resistance, Oncologist, 18, 7, pp. 850-864, (2013)

← 1 2 3 4 →